TN2013000257A1 - Immunosuppressant formulations - Google Patents

Immunosuppressant formulations

Info

Publication number
TN2013000257A1
TN2013000257A1 TNP2013000257A TN2013000257A TN2013000257A1 TN 2013000257 A1 TN2013000257 A1 TN 2013000257A1 TN P2013000257 A TNP2013000257 A TN P2013000257A TN 2013000257 A TN2013000257 A TN 2013000257A TN 2013000257 A1 TN2013000257 A1 TN 2013000257A1
Authority
TN
Tunisia
Prior art keywords
api
immunosuppressant
formulations
compound
immunosuppressant formulations
Prior art date
Application number
TNP2013000257A
Other languages
English (en)
Inventor
Philippe Bouillot
Emeric Reynaud
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000257A1 publication Critical patent/TN2013000257A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TNP2013000257A 2011-01-07 2013-06-14 Immunosuppressant formulations TN2013000257A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07
PCT/EP2012/050151 WO2012093161A1 (fr) 2011-01-07 2012-01-05 Formulations d'immunosuppresseurs

Publications (1)

Publication Number Publication Date
TN2013000257A1 true TN2013000257A1 (en) 2014-11-10

Family

ID=44022942

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000257A TN2013000257A1 (en) 2011-01-07 2013-06-14 Immunosuppressant formulations

Country Status (34)

Country Link
US (3) US20130273161A1 (fr)
EP (2) EP3590507A1 (fr)
JP (2) JP6111202B2 (fr)
KR (2) KR101951966B1 (fr)
CN (1) CN103458877B (fr)
AR (2) AR084801A1 (fr)
AU (1) AU2012204835B2 (fr)
CA (1) CA2823616C (fr)
CL (1) CL2013001979A1 (fr)
CO (1) CO6761402A2 (fr)
CY (1) CY1122182T1 (fr)
DK (1) DK2661261T3 (fr)
EA (1) EA026144B9 (fr)
EC (1) ECSP13012812A (fr)
ES (1) ES2751920T3 (fr)
GT (1) GT201300178A (fr)
HR (1) HRP20191842T1 (fr)
HU (1) HUE045612T2 (fr)
IL (1) IL227094B (fr)
JO (1) JO3619B1 (fr)
LT (1) LT2661261T (fr)
MA (1) MA34897B1 (fr)
MX (2) MX371290B (fr)
MY (1) MY161162A (fr)
PE (1) PE20140216A1 (fr)
PL (1) PL2661261T3 (fr)
PT (1) PT2661261T (fr)
SG (1) SG191286A1 (fr)
SI (1) SI2661261T1 (fr)
TN (1) TN2013000257A1 (fr)
TW (2) TWI583380B (fr)
UA (1) UA114283C2 (fr)
WO (1) WO2012093161A1 (fr)
ZA (1) ZA201304465B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170027907A1 (en) * 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen
PT3129006T (pt) * 2014-04-10 2021-04-09 Novartis Ag Formulação imunossupressora
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP4230208A1 (fr) * 2015-07-03 2023-08-23 Astellas Pharma Inc. Composition pharmaceutique stable pour administration orale
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP7271517B2 (ja) 2017-09-27 2023-05-11 ノバルティス アーゲー シポニモドを含む非経口製剤
CA3073910A1 (fr) 2017-09-29 2019-04-04 Novartis Ag Schema posologique de siponimod
RU2020114751A (ru) 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (fr) 2020-04-23 2021-10-28 Novartis Ag Schéma posologique pour l'utilisation de siponimod pour le traitement du syndrome de détresse respiratoire aiguë
WO2023172508A1 (fr) * 2022-03-09 2023-09-14 Isp Investments Llc Composition d'excipient co-traitée

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225964B1 (en) 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
CN100384398C (zh) * 2002-11-07 2008-04-30 日本泽托克株式会社 口腔用组合物用基质及口腔用组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
AU2008310846C1 (en) * 2007-10-12 2022-10-06 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
BRPI0916968A2 (pt) * 2008-08-18 2015-11-24 Novartis Ag compostos para o tratamento de neuropatias periféricas, formulações farmacêuticas compreendendo os referidos compostos, e usos dos mesmos
RU2011129230A (ru) 2008-12-18 2013-01-27 Новартис Аг Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
UY32330A (es) * 2008-12-18 2010-07-30 Novartis Ag Novedosa forma de sal de ácido 1-(4-{1-[e-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, formas polimórficas, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
CN103204794A (zh) * 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
TWI472327B (zh) 2008-12-22 2015-02-11 Novartis Ag Ｓ１ｐ受體激動劑劑量療法

Also Published As

Publication number Publication date
CY1122182T1 (el) 2020-11-25
DK2661261T3 (da) 2019-10-21
LT2661261T (lt) 2019-10-25
CO6761402A2 (es) 2013-09-30
EA201391018A1 (ru) 2013-11-29
KR20140037815A (ko) 2014-03-27
AR124662A2 (es) 2023-04-19
KR101951966B1 (ko) 2019-02-25
ZA201304465B (en) 2014-02-26
JP6111202B2 (ja) 2017-04-05
JP2017141248A (ja) 2017-08-17
GT201300178A (es) 2014-12-30
EA026144B1 (ru) 2017-03-31
CA2823616A1 (fr) 2012-07-12
EP2661261B1 (fr) 2019-07-31
SG191286A1 (en) 2013-07-31
JP6324569B2 (ja) 2018-05-16
PE20140216A1 (es) 2014-03-01
PL2661261T3 (pl) 2020-01-31
JO3619B1 (ar) 2020-08-27
MX357304B (es) 2018-07-04
CL2013001979A1 (es) 2013-11-22
NZ612420A (en) 2015-05-29
CA2823616C (fr) 2019-01-29
CN103458877A (zh) 2013-12-18
SI2661261T1 (sl) 2019-11-29
HUE045612T2 (hu) 2020-01-28
MA34897B1 (fr) 2014-02-01
TWI583380B (zh) 2017-05-21
TW201249438A (en) 2012-12-16
WO2012093161A1 (fr) 2012-07-12
AU2012204835B2 (en) 2015-07-09
PT2661261T (pt) 2019-10-25
ES2751920T3 (es) 2020-04-02
TWI610672B (zh) 2018-01-11
IL227094B (en) 2019-03-31
TW201609092A (zh) 2016-03-16
EP2661261A1 (fr) 2013-11-13
EP3590507A1 (fr) 2020-01-08
JP2014501770A (ja) 2014-01-23
UA114283C2 (uk) 2017-05-25
BR112013017302A2 (pt) 2016-10-25
US20220064110A1 (en) 2022-03-03
MX2013007909A (es) 2013-08-29
EA026144B9 (ru) 2021-10-26
US20200199069A1 (en) 2020-06-25
US20130273161A1 (en) 2013-10-17
MY161162A (en) 2017-04-14
ECSP13012812A (es) 2013-09-30
KR20190025727A (ko) 2019-03-11
MX371290B (es) 2020-01-24
AU2012204835A1 (en) 2013-08-01
HRP20191842T1 (hr) 2019-12-27
AR084801A1 (es) 2013-06-26
KR102166885B1 (ko) 2020-10-19
CN103458877B (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
TN2013000257A1 (en) Immunosuppressant formulations
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MY187718A (en) Pharmaceutical formulations
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA201692298A1 (ru) Производные карбоксамидов
PH12015501386A1 (en) Tricyclic compounds
WO2014016754A3 (fr) Compositions pharmaceutiques d'inhibiteur de la pompe à protons
TN2014000060A1 (en) Benzothiazolone compound
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
TN2012000617A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
PH12016502247A1 (en) Carboxamide derivatives